Vaccine maker Bharat Biotech, Biovet and Sapigen Biologix, on Monday, signed a collaborative research agreement with CSIR-Indian Institute of Chemical Technology (IICT) to collaborate on development of novel platform technologies for bio-therapeutics and vaccines to support affordable healthcare solutions for humans and animals.
As per the agreement, the collaborators would identify mutually interesting projects to pursue, a CSIR-IICT release said. Also Read: Education ministry launches more than 100 NCERT comic books
As a part of the Master Collaborative Agreement (MCA), the Industry collaborators shall provide necessary financial support to CSIR-IICT for developing key raw materials required by the collaborators, and also perform “in-vitro and in vivo studies” for further development of potential vaccine candidates and bio-therapeutics formulations to be designed by the collaborators. The broad-based MCA enables the partners to take up futuristic development activities in other related areas as well, it said.
The MCA follows the contribution by CSIR-IICT during February 2021, in developing a synthetic process route for adjuvant molecule TLR 7/8 to BBIL for Covaxin, the indigenous vaccine rolled out by Bharat Biotech. Also Read: Tata Motors signs MoU with SBI to finance Tata’s small, light commercial vehicles
The partners intend to strengthen the “excellent working relationship” between the organisations, by conducting studies on futuristic vaccines, bio-therapeutic formulations, delivery strategies and also explore innovative solutions to the vaccination administration process, the release added.